Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SNY
- Company Sanofi
- Price $53.66
- Changes Percentage -2.31
- Change -1.27
- Day Low $53.51
- Day High $54.65
- Year High $58.97
- Year Low $42.63
- Market Cap $134,534,205,600
- Price Avg 50 EMA (D) $56.03
- Price Avg 200 EMA (D) $50.73
- Exchange NASDAQ
- Volume 2,233,904
- Average Volume 1,758,050
- Open $54.55
- Previous Close $54.93
- EPS 1.82
- PE 29.48
- Earnings Announcement 2024-10-25 00:00:00
- Shares Outstanding $2,507,160,000
Company brief: SANOFI (SNY )
- Healthcare
- Drug Manufacturers - General
- Mr. Paul Hudson
- https://www.sanofi.com
- FR
- N/A
- 07-01-2002
- US80105N1054
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
SNY Corporation News
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
zacks.com -- SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella....
French govt set to take stake in Sanofi unit after PE sale
proactiveinvestors.co.uk -- France is reportedly set to acquire a small stake in Sanofi SA's (ADR) (NYSE:SNY) consumer healthcare unit as the pharmaceutical company proceeds with a €16 billion deal to sell half of the busine...
Sanofi enters exclusive talks with CD&R for Opella sale
reuters.com -- Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R)....
Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare
globenewswire.com -- Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant...
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI
reuters.com -- France will take a stake in Sanofi 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. priv...
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
zacks.com -- Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers....
PAI Partners makes higher offer for Sanofi's Opella, says Le Monde
reuters.com -- French private equity firm PAI Partners has submitted a new, higher offer for Sanofi's consumer health business Opella, the Le Monde newspaper said on Thursday, as PAI seeks to outbid U.S. rival Clayt...
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
globenewswire.com -- Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targete...